Oruka Shares Rise More Than 13% After Positive Psoriasis Trial Results
Guggenheim reaffirmed its bullish outlook on Oruka Therapeutics, saying its experimental psoriasis treatment could generate $7 billion in peak sales. Shares were up more than 13% at the time of writing.